H101 virus plus TACE for recurrent head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests combining a cancer-killing virus (H101) with a procedure that delivers chemo directly to the tumor (TACE) for people with advanced head and neck cancers that have not responded to at least two standard treatments. It aims to see if this combination can help shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 79 years old.
- You have a head or neck cancer (like throat, mouth, voice box, or nose cancer) that has gotten worse after at least two standard treatments.
- You are well enough to be out of bed at least half the day (ECOG score 0-2).
- Your blood counts show enough infection-fighting cells and platelets.
- Your liver and kidney function are within safe limits.
- You agree to follow the study plan and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug (SYS6010) compared with standard single-drug treatments for advanced head and neck cancer that has not responded to previous therapies. The goal is to see if this new drug can shrink tumors or slow cancer growth better than the usual options.
This trial tests giving a combination of two drugs (an immunotherapy drug called a PD-1 inhibitor and a targeted therapy called cetuximab) before surgery to shrink head and neck cancers. The goal is to see if this approach lowers the chance of the cancer coming back after surgery.
This trial tests whether combining two immunotherapy drugs before surgery is better than one alone for advanced head and neck cancer. The goal is to see if the combination can shrink tumors more and improve outcomes.
This study tests a combination of three drugs for people with head and neck cancer that has come back or spread. The goal is to see if this combination can shrink tumors or slow the disease.
This Phase 1 trial tests HRYZ-T101 injection for people whose solid cancer is HPV18-positive and who have the HLA-DRB1*0901 immune marker. It is meant for people whose cancer has returned or spread and who have few or no effective treatment options.
This trial tests a new treatment where a specially designed virus carrying an anti-cancer gene is injected directly into tumors in the head and neck area. It's for patients whose cancer has come back or spread after prior chemotherapy and who cannot have surgery or radiation.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.